Amgen Boosts Portfolio with Positive Phase 3 Results for Dazodalibep

Amgen has released positive topline Phase 3 OASIZ 301 data for dazodalibep in adults with moderate-to-severe systemic Sjögren’s disease. The results show statistically significant ESSDAI improvements sustained through Week 48 and a safety profile described as generally mild to moderate.

This is a potential first-in-class CD40L antagonist targeting a disease area with no approved disease-modifying therapies, which could broaden Amgen's autoimmune portfolio and support the case for its late-stage pipeline focus. The company's investment narrative emphasizes the mix of established blockbuster therapies, biosimilars, and a deep late-stage pipeline.

The Phase 3 win strengthens the case that autoimmune R&D spend is translating into late-stage assets, but does not change the near-term focus on execution across multiple programs. Key short-term factors include Amgen's ability to convert its large pipeline into approved, commercially relevant therapies while managing higher R&D and manufacturing investment.

Intensifying competition and drug price pressure could squeeze growth and margins if new launches and indications do not scale well. The IMDELLTRA monitoring label update is especially relevant beside dazodalibep, as it shows Amgen working on both sides of the story: expanding the reach of newer oncology products while advancing autoimmune drug candidates aimed at underserved conditions such as Sjögren’s disease.